RNA-LNP human vaccine model
Human prophylactic vaccine programs are evolving beyond traditional inactivated, attenuated, and recombinant protein approaches toward nucleic acid-based and LNP-enabled platforms. mRNA, circRNA, saRNA, and DNA/RNA-enabled vaccine strategies can accelerate antigen design, enable rapid platform adaptation, and support more flexible responses to emerging infectious disease threats.
Key CMC questions
For human infectious disease vaccine programs, the core CMC questions include antigen sequence design, RNA payload quality, expression performance, LNP formulation robustness, immunogenicity-related quality attributes, process scalability, sterility assurance, stability, and regulatory-ready documentation.
Integrated RNA-LNP CMC control
Compared with conventional vaccine platforms, RNA-LNP vaccines require tightly integrated control of RNA drug substance, LNP drug product, analytical methods, and GMP manufacturing from early development. Early decisions around RNA construct design, purification strategy, formulation route, and release testing can directly affect immunogenicity, stability, and clinical translation.
CATUG integrated support
CATUG supports human vaccine programs through plasmid DNA and IVT template preparation, mRNA/circRNA/saRNA drug substance manufacturing, LNP/tLNP drug product formulation, analytical development, GMP manufacturing, fill-finish, stability studies, and CMC documentation. Our RNA platform includes process development capabilities for dsRNA reduction, residual impurity control, RNA integrity optimization, purification strategy development, and stage-appropriate analytical control.
LNP formulation and scale-up support
On the drug product side, CATUG supports LNP formulation screening, lipid composition optimization, encapsulation development, particle size and PDI control, RNA loading and encapsulation efficiency optimization, and scale-up. Our experience includes MaxMix™ LNP processes designed to improve manufacturing scalability, process robustness, and transition from early formulation screening to GMP-oriented production.
Flexible engagement model
Depending on project stage, CATUG can support selected modules such as plasmid, RNA DS, LNP DP, analytics, GMP manufacturing, or fill-finish, or provide an integrated CMC workflow from early feasibility to IIT, IND-enabling, and clinical-stage vaccine development.
Cost-sensitive animal vaccine CMC model
Animal vaccine programs require practical, scalable, and cost-sensitive CMC solutions for livestock, companion animal, and veterinary infectious disease applications. Nucleic acid-based vaccine approaches, including mRNA, circRNA, saRNA, and DNA/RNA-enabled strategies, may provide flexible antigen design, rapid strain update potential, and platform-based development advantages for emerging or recurrent animal infectious diseases.
Veterinary-specific CMC priorities
Compared with human vaccine programs, veterinary vaccine development often places greater emphasis on manufacturing cost, production yield, supply scalability, stability, dosing practicality, and fit-for-purpose quality standards. For RNA- or LNP-enabled animal vaccine programs, CMC strategy must balance product performance with COGS, process robustness, batch consistency, and practical deployment requirements.
CATUG integrated support
CATUG supports animal vaccine development through plasmid template preparation, RNA drug substance manufacturing, LNP drug product formulation, analytical development, process scale-up, stability studies, and stage-appropriate documentation. Our platform can support mRNA, circRNA, saRNA, and DNA/RNA-related workflows, allowing clients to evaluate different payload formats and expression profiles based on antigen type, target species, dosing strategy, and development objective.
Flexible quality and cost strategy
For cost-sensitive veterinary applications, CATUG can provide flexible, stage-appropriate solutions rather than forcing clients into oversized clinical-GMP packages too early. Depending on project needs, we can support research-grade, GMP-like, or GMP-oriented materials with fit-for-purpose analytics, helping clients balance quality, speed, scalability, and COGS from feasibility through process development and manufacturing translation.
Why CATUG for animal vaccines
CATUG’s integrated RNA, LNP, analytical, and manufacturing capabilities help animal health innovators translate vaccine concepts into developable and scalable CMC programs.
CATUG supports RNA-LNP vaccine programs with integrated plasmid / IVT template preparation, mRNA / circRNA / saRNA drug substance manufacturing, LNP / tLNP formulation, analytical development, GMP drug product manufacturing, fill-finish, stability, and CMC documentation, with human vaccine development as the primary focus.
RNA-LNP vaccine development requires integrated control of antigen design, RNA payload quality, LNP formulation robustness, immunogenicity-related quality attributes, sterility assurance, stability strategy, and regulatory-ready documentation.
Human vaccine programs require tightly integrated RNA DS, LNP DP, analytical development, GMP manufacturing, fill-finish, stability, and regulatory documentation from early feasibility through IND-enabling and clinical translation.
Animal vaccine programs often require practical, scalable, and cost-sensitive CMC solutions for livestock, companion animal, and veterinary infectious disease applications.
Human vaccine CMC requires RNA payload control, LNP robustness, stability strategy, GMP execution, and commercial readiness.
Controlled RNA identity, integrity, purity, and stage-appropriate release strategy.
Formulation control for particle attributes, encapsulation, and batch consistency.
Scalable LNP process translation from development to GMP production.
Frozen storage, lyophilization, reconstitution, and stability support.
GMP execution and commercial-stage process readiness mindset.
Supports antigen-encoding mRNA, circRNA, and saRNA payload development for human vaccine applications, including expression profile evaluation, RNA integrity control, purification, and stage-appropriate RNA DS manufacturing.
Supports plasmid construction, IVT template preparation, IVT, capping or circularization, purification, UF/DF, residual impurity control, RNA identity, purity, integrity, and stage-appropriate analytical control.
Supports IND-enabling CMC preparation with regulatory-aligned source documents, analytical reports, batch records, CoA, stability data, and technical support for China and U.S. filing-oriented programs.
Supports LNP formulation screening, lipid composition optimization, RNA loading, encapsulation efficiency, size / PDI control, MaxMix™-enabled scale-up, and GMP-oriented DP process development.
Supports frozen storage, cryoprotectant screening, freeze-thaw evaluation, lyophilization, reconstitution, size / PDI / EE stability, and stage-appropriate stability study design.
Supports engineering and GMP batches, sterile fill-finish, release testing, batch records, stability, process robustness, and commercial-stage manufacturing readiness for RNA-LNP vaccine programs.
Human RNA-LNP vaccine programs require early alignment of antigen sequence design, plasmid / IVT template strategy, RNA DS development, LNP formulation, stability strategy, GMP execution, and China / U.S. IND-oriented regulatory documentation.
Built for human infectious disease vaccine programs where RNA quality, LNP robustness, sterility assurance, -20°C / lyophilization stability strategy, CN / U.S. IND-oriented documentation, and commercial-stage readiness must be considered together.